ArticleFrontiers in medicine2026
Clinical and biological impact of caffeine therapy in premature infants with apnea of prematurity: a prospective observational study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methylxanthines are the first-line medication in apnea of prematurity. However, serum concentrations exhibit marked variability due to immature hepatic metabolism and drug-drug interactions. Objectives: This study aimed to evaluate premature newborns diagnosed with apnea of prematurity and highlight the role of therapeutic drug monitoring in preventing complications related to overaccumulation. Methods: This prospective observational clinical study was conducted on 325 premature neonates, divided into high caffeine citrate study group with serum titer >50 μg/mL (HC, Results: Major complications in caffeine group were intracranial hemorrhage (5.33%) and convulsions followed by death (4.00%) as, while the CoG demonstrated fewer adverse outcomes and more favorable clinical evolution. Conclusion: Intermittent administration of standard methylxanthine doses or adjustment of therapeutic doses, guided by serial monitoring of serum caffeine citrate titer, may improve clinical outcomes in critical cases, reduce adverse drug effects, and support safer and individualized therapeutic management of apnea of prematurity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.